Rocuronium
A neuromuscular blocking agent used during surgery and intubation to produce muscle relaxation by blocking acetylcholine receptors at the neuromuscular junction. Its effects can be rapidly reversed with sugammadex, making it a preferred choice in emergency airway management.
Молекулярная масса
529,8000 g/mol
LogP
5,00
TPSA
59,00 Ų
Правило пяти Липинского
Соответствует
Терапевтические области
Механизм действия
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
2D Структура
Cite this structure
Embed this structure
SMILES
C=CC[N+]1([C@H]2C[C@H]3[C@@H]4CC[C@H]5C[C@H](O)[C@@H](N6CCOCC6)C[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2OC(C)=O)CCCC1
InChI
InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1
Molecular Formula
C32H53N2O4+
HBD / HBA
1 / 5
Вращаемые Связи
6
Тяжёлые Атомы
38
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Часто задаваемые вопросы
A neuromuscular blocking agent used during surgery and intubation to produce muscle relaxation by blocking acetylcholine receptors at the neuromuscular junction. Its effects can be rapidly reversed with sugammadex, making it a preferred choice in emergency airway management.
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Yes, Rocuronium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201244. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 441290. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="rocuronium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/rocuronium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/rocuronium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/rocuronium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="rocuronium"></drugfyi-drug>